<DOC>
	<DOCNO>NCT00475696</DOCNO>
	<brief_summary>Examine efficacy safety duloxetine subject symptoms bladder overactivity due pure detrusor instability sensory urgency . Subjects study permitted escalate de-escalate 80 mg/day 120 mg/day consultation investigator base adverse event .</brief_summary>
	<brief_title>Urge Incontinence Bladder Overactivity Study</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Are female outpatient . Are least 18 year age . Are ambulatory able use toilet independently without difficulty . Have language cognitive barrier , agree comply requirement protocol , sign write informed consent document prior entry study . Are woman nonchildbearing potential reason hysterectomy natural menopause , woman childbearing potential agreeing use medically accept mean contraception ( example , intrauterine device [ IUD ] , oral injectable contraceptive , implant , barrier device , sterilization , abstinence , sex vasectomize male partner ) duration study . Women use oral contraceptive hormone replacement therapy must stable dose regimen 3 month prior study . Have postvoid residual ( PVR ) volume 100 mL within 15 minute spontaneous void . Patients must predominant symptom bladder overactivity define meeting follow criterion : 1. bothersome urinary urgency ( sensation urgent need void fear leakage ) minimum 3 consecutive month prior study entry , urge urinary incontinence ( UUI ; involuntary loss urine precede urgency ) minimum 3 consecutive month prior study entry 2. abnormal frequency micturition ( average void interval 2 hour less [ 2 ] waking hour ) confirm least two day record screen dairy collect Visit 1 . Have UDS establish DI sensory urgency ( determined Visit 2 ) . Have respond appropriately screening question prior Visit 1 . Use medication duloxetine urinary incontinence within 1 day prior start study medication time study . Use monoamine oxidase inhibitor ( MAOIs ) exclude medication within 14 day prior start study medication time study . Have follow : A significant arrhythmia despite antiarrhythmic medication , uncontrolled angina , significant abnormality ECG within 6 month prior study entry , opinion investigator , require investigation intervention . Any active cardiac ischemic condition , include myocardial infarction within 6 month prior study entry Uncontrolled poorly control hypertension Active seizure disorder Unstable diabetes mellitus Spinal cord lesion , multiple sclerosis , neurological abnormality affect low urinary tract History severe allergy require emergency medical treatment multiple adverse drug reaction History chronic lung disease associate four ( 4 ) acute exacerbation per year result severe cough Active chronic hepatitis A , B , C. Are pregnant , pregnant previous 6 month , resume normal menstruation 3 month prior study entry due breastfeeding . Are breastfeed . Have receive treatment within last 30 day drug duloxetine receive regulatory approval country indication time study entry . Have condition , limitation , disease , abnormal laboratory value could , judgment investigator , preclude evaluation response duloxetine . Are directly affiliate conduct study , immediate family someone directly affiliate conduct study ( , Lilly employee , investigator , site personnel , immediate family ) . Immediate family define spouse , parent , child sibling , whether biological legally adopt .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>